Role of novel imaging in the management of prostate cancer

Karen M Xu; Ronald C Chen; David M Schuster; Ashesh B Jani

doi:10.1016/j.urolonc.2019.04.008

Role of novel imaging in the management of prostate cancer

Urol Oncol. 2019 Sep;37(9):611-618. doi: 10.1016/j.urolonc.2019.04.008. Epub 2019 May 6.

Authors

Karen M Xu¹, Ronald C Chen², David M Schuster³, Ashesh B Jani⁴

Affiliations

¹ Department of Radiation Oncology and Winship Cancer Institute of Emory University, Emory University, Atlanta, GA.
² Department of Radiation Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
³ Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University Hospital, Atlanta, GA.
⁴ Department of Radiation Oncology and Winship Cancer Institute of Emory University, Emory University, Atlanta, GA. Electronic address: abjani@emory.edu.

PMID: 31072791
DOI: 10.1016/j.urolonc.2019.04.008

Abstract

This review summarizes novel imaging in the management of prostate cancer including multiparametric MRI, PET-CT scans with different radiotracers including ¹¹C-acetate, ¹¹C-choline, ¹⁸F-choline, ¹⁸F sodium fluoride, prostate-specific membrane antigen, and anti-1-amino-3-[18F] fluorocyclobutane-1-carboxylic acid (fluciclovine).

Keywords: MRI; Molecular imaging; PET scan; Prostate cancer.

Publication types

Review

MeSH terms

Humans
Male
Prostatic Neoplasms / diagnostic imaging*
Prostatic Neoplasms / therapy